Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Moleculin Biotech, Inc. (MBRX) had Return on Equity of -223.64% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-33.66M |
|
-- |
|
-- |
|
$25.10M |
|
$-25.10M |
|
$-8.46M |
|
$-33.56M |
|
$-33.56M |
|
$-33.56M |
|
$-33.56M |
|
$-33.56M |
|
$-33.56M |
|
$-25.10M |
|
$-25.01M |
|
1.18M |
|
1.18M |
|
$-28.42 |
|
$-28.42 |
|
| Balance Sheet Financials | |
$9.69M |
|
$0.08M |
|
$12.44M |
|
$22.13M |
|
$6.85M |
|
-- |
|
$0.27M |
|
$7.12M |
|
$15.01M |
|
$3.86M |
|
$15.01M |
|
3.20M |
|
| Cash Flow Statement Financials | |
$-22.73M |
|
-- |
|
$27.28M |
|
$4.28M |
|
$8.88M |
|
$4.60M |
|
$1.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-22.73M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-223.64% |
-869.88% |
|
-151.68% |
|
-223.64% |
|
$4.69 |
|
$-19.19 |
|
$-19.19 |
|